Open AccessFuture prospects for breast cancer immunotherapy
Author(s) -
Владимир Семиглазов,
А. И. Целуйко,
Р. В. Донских,
Petr Krivorotko,
Г. А. Дашян,
В. В. Семиглазов,
А. В. Комяхов
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-19-12-16
Subject(s) - immunotherapy , medicine , breast cancer , adjuvant , regimen , oncology , monoclonal antibody , cancer , cancer immunotherapy , immunology , antibody
Immunotherapy has already become an important component of the standard treatment of patients with advanced cancer. Most treatment methods include monoclonal antibodies (mAbs) that block immune checkpoints, in particular, the programmed cell death 1 (PD-1) receptor and its ligand 1 (PD-L1) or are directed against T-lymphocyte-associated protein 4 (CTLA-4). The future prospects for immuno-oncology will be to determine whether these agents can be more effective if administered in a postoperative adjuvant or in a neoadjuvant regimen prior to surgical treatment. Vaccine therapy has shown promising results, and this therapy is especially attractive due to absence of pronounced toxicity.